Filing and reporting period
Important source mismatch: The supplied filing is Frequency Therapeutics, Inc.’s Form 10-K, not a filing for Korro Bio, Inc. It covers the fiscal year ended December 31, 2020; the filing was signed March 29, 2021. The figures below therefore describe Frequency Therapeutics.
Frequency was a clinical-stage biotechnology company developing FX-322 for sensorineural hearing loss (SNHL) and researching a progenitor-cell activation platform, including a preclinical multiple sclerosis program. It had no approved products and no product-sales revenue.
Financial results and position
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | $37.0 million | $28.9 million |
| Research and development expense | $37.4 million | $18.8 million |
| General and administrative expense | $27.1 million | $14.8 million |
| Operating loss | $27.6 million | $20.7 million |
| Net loss | $26.5 million | $18.7 million |
| Net loss per share, basic and diluted | $0.82 | $2.29 |
| Net cash used in operating activities | $45.2 million | Cash provided: $34.2 million |
Revenue was recognized over time from Astellas Pharma’s $80 million upfront payment under the collaboration agreement, not from product sales. The company recognized $37.0 million in 2020 and reported $14.1 million of current deferred revenue at year-end; it expected to recognize the remaining upfront-payment revenue in 2021. The 2019 results included a one-time $16.0 million royalty expense to MIT related to the Astellas payment; no royalty was paid in 2020. Profit margins are not meaningful for this pre-commercial, loss-making business.
At December 31, 2020, cash, cash equivalents and short-term investments totaled $220.3 million, working capital was $198.4 million, total assets were $264.7 million, and total liabilities were $72.2 million. The company had $15.0 million of term debt and $192.5 million of stockholders’ equity. It reported no short-term marketable securities at year-end; cash and cash equivalents were $220.3 million. Management estimated existing cash and investments would fund operations into 2023, subject to assumptions and clinical-development costs.
Cash flows included $56.7 million provided by financing activities, primarily from a $40.1 million net private placement and $15.0 million term-loan proceeds. Investing activities provided $10.4 million, principally from net redemptions of securities. The company reported $47.5 million of future minimum operating lease payments, including its new Lexington facility.
For the fourth quarter of 2020, revenue was $10.0 million and net loss was $10.2 million. Quarterly results are unaudited and not necessarily indicative of future performance.
Material changes versus 2019
- Revenue increased by $8.0 million as more of the Astellas upfront payment was recognized; it remains collaboration revenue rather than product sales.
- R&D expense rose by $18.6 million, including increased FX-322 clinical-development spending and platform, early research and staffing costs.
- G&A expense increased by $12.3 million, with higher personnel, stock-based compensation, directors’ and officers’ insurance, and public-relations costs.
- Net loss increased by $7.8 million. The comparison is affected by the $16.0 million MIT royalty recorded in 2019 and absent in 2020.
- Operating cash flow shifted from $34.2 million provided to $45.2 million used, principally reflecting the reduction in deferred revenue as the Astellas upfront payment was recognized.
- In July 2020, the company raised $40.1 million net through a common-stock private placement; in December, it borrowed $15.0 million under a term loan.
Outlook, developments and risks
- FX-322 clinical evidence was mixed. After year-end, the company reported Phase 2a interim day-90 results: four weekly injections did not improve hearing measures versus placebo, with no discernible treatment benefit. Management said repeated dosing appeared to dampen the hearing signal and noted unexpectedly large placebo-group improvements. No treatment-related serious adverse events were reported.
- Also after year-end, a separate Phase 1b single-injection study reported that 34% of 32 completers achieved an absolute word-recognition improvement of at least 10% in the treated ear, statistically significant versus the untreated ear (p<0.05). These are preliminary company-reported results and do not establish approval or commercial efficacy.
- Management planned to report the Phase 2a day-210 analysis late in the second quarter of 2021, and expected age-related hearing-loss Phase 1b results in Q2 2021 and severe-SNHL Phase 1b results in Q3 2021. These are forward-looking expectations, not reported outcomes.
- The company said it would emphasize single-dose FX-322 development following the Phase 2a interim results. FX-322 had FDA Fast Track designation, but remained investigational and would require further clinical and regulatory work.
- The MS program remained research/preclinical; no development candidate had been selected. Management described preliminary preclinical findings as promising.
- Key risks include dependence on FX-322, uncertain clinical and regulatory success, need for future financing, reliance on contract manufacturers and research organizations, intellectual-property and license obligations, competition, reimbursement uncertainty, and possible COVID-19-related delays or operating disruption. The company reported that trial-site enrollment pauses had occurred during 2020.
- Astellas holds development and commercialization rights outside the United States. Potential development milestones of up to $230 million, commercial milestones of up to $315 million, and tiered royalties are contingent on future progress and sales; they are not assured funding.
- The $15 million term loan bears interest at the greater of 1.50% plus prime or 4.75%, has interest-only payments through November 2022, and amortizes through May 2024. It is secured by substantially all assets other than intellectual property; a $150,000 final payment is also due under specified conditions.
- The company reported no material legal proceedings, no off-balance-sheet arrangements, and effective disclosure controls and internal control over financial reporting. The auditor issued an unqualified opinion on the financial statements.
Most important facts to verify
- Verify the issuer identity: this 10-K is for Frequency Therapeutics, not Korro Bio.
- Review the complete Phase 2a day-210 results and subsequent trial disclosures, including how the placebo response and study design affect interpretation.
- Assess whether single-dose FX-322 findings are replicated in adequately powered studies and whether regulators accept the proposed endpoints and trial design.
- Check actual cash use and financing after year-end against management’s runway estimate into 2023, including the cost of planned trials and the term-loan repayment schedule.
- Confirm the timing and recognition of the remaining Astellas upfront revenue, and distinguish recognized revenue from contingent milestones, royalties and future collaboration reimbursements.
- Review the full loan and lease terms, collaboration cost-sharing obligations, and any related-party disclosures; the filing states that an MIT inventor who is also a director received $1.98 million from MIT under its policy in 2020.